Shares of Inventiva S.A. (NASDAQ: IVA) tumbled 5.45% in pre-market trading on Monday following the release of the company's disappointing quarterly financial results. The biopharmaceutical firm reported a substantial earnings miss that caught investors off guard, leading to the sharp decline in stock price.

Inventiva reported a quarterly loss of $1.84 per share, significantly wider than the analyst consensus estimate of a $0.41 loss. This represents a staggering 348.05% miss compared to expectations and an 81.88% increase in losses from the same period last year. On the revenue front, the company posted sales of $5.05 million, slightly below the projected $5.31 million, missing estimates by 4.90%. Despite the miss, it's worth noting that this figure represents a substantial increase from the $44,141 reported in the same quarter of the previous year.

The dramatic earnings miss raises concerns about Inventiva's financial health and operational efficiency. While the company has shown significant revenue growth year-over-year, the widening losses may signal challenges in controlling costs or difficulties in scaling its operations. Investors will likely be looking for explanations from management regarding the factors contributing to the increased losses and any strategies in place to improve profitability in the coming quarters. The pre-market stock plunge reflects the market's immediate reaction to these concerns, and it remains to be seen how the company will address these issues to regain investor confidence.